Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 274

1.

Image-Derived Input Functions for Quantification of A1 Adenosine Receptors Availability in Mice Brains Using PET and [18F]CPFPX.

He X, Wedekind F, Kroll T, Oskamp A, Beer S, Drzezga A, Ermert J, Neumaier B, Bauer A, Elmenhorst D.

Front Physiol. 2020 Jan 29;10:1617. doi: 10.3389/fphys.2019.01617. eCollection 2019.

2.

Network degeneration in Parkinson's disease: multimodal imaging of nigro-striato-cortical dysfunction.

Ruppert MC, Greuel A, Tahmasian M, Schwartz F, Stürmer S, Maier F, Hammes J, Tittgemeyer M, Timmermann L, van Eimeren T, Drzezga A, Eggers C.

Brain. 2020 Feb 14. pii: awaa019. doi: 10.1093/brain/awaa019. [Epub ahead of print]

PMID:
32057084
3.

[18F-FDG PET/CT in head and neck tumors].

Dietlein M, Klußmann JP, Drzezga A.

Nuklearmedizin. 2020 Feb;59(1):8-11. doi: 10.1055/a-1067-4709. Epub 2020 Feb 4. German. No abstract available.

PMID:
32018298
4.

18F-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging.

Werner RA, Derlin T, Lapa C, Sheikbahaei S, Higuchi T, Giesel FL, Behr S, Drzezga A, Kimura H, Buck AK, Bengel FM, Pomper MG, Gorin MA, Rowe SP.

Theranostics. 2020 Jan 1;10(1):1-16. doi: 10.7150/thno.37894. eCollection 2020. Review.

5.

From molecules to system failure: translational frontiers of multimodal imaging in neurodegenerative diseases.

van Eimeren T, Drzezga A.

Eur J Nucl Med Mol Imaging. 2019 Dec;46(13):2816-2818. doi: 10.1007/s00259-019-04562-7. Epub 2019 Oct 30. No abstract available.

PMID:
31667539
6.

Intraindividual comparison of 18F-PSMA-1007 with renally excreted PSMA ligands for PSMA-PET imaging in patients with relapsed prostate cancer.

Dietlein F, Kobe C, Hohberg M, Zlatopolskiy BD, Krapf P, Endepols H, Täger P, Hammes J, Heidenreich A, Persigehl T, Neumaier B, Drzezga AE, Dietlein M.

J Nucl Med. 2019 Oct 18. pii: jnumed.119.234898. doi: 10.2967/jnumed.119.234898. [Epub ahead of print]

PMID:
31628219
7.

Local and Global Changes in Brain Metabolism during Deep Brain Stimulation for Obsessive-Compulsive Disorder.

Baldermann JC, Bohn KP, Hammes J, Schüller CB, Visser-Vandewalle V, Drzezga A, Kuhn J.

Brain Sci. 2019 Aug 30;9(9). pii: E220. doi: 10.3390/brainsci9090220.

8.

Biodistribution and radiation dosimetry of [18F]-JK-PSMA-7 as a novel prostate-specific membrane antigen-specific ligand for PET/CT imaging of prostate cancer.

Hohberg M, Kobe C, Krapf P, Täger P, Hammes J, Dietlein F, Zlatopolskiy BD, Endepols H, Wild M, Neubauer S, Heidenreich A, Neumaier B, Drzezga A, Dietlein M.

EJNMMI Res. 2019 Jul 25;9(1):66. doi: 10.1186/s13550-019-0540-7.

9.

An 18F-Labeled PSMA Ligand for PET/CT of Prostate Cancer: First-in-Humans Observational Study and Clinical Experience with 18F-JK-PSMA-7 During the First Year of Application.

Dietlein F, Hohberg M, Kobe C, Zlatopolskiy BD, Krapf P, Endepols H, Täger P, Hammes J, Heidenreich A, Neumaier B, Drzezga A, Dietlein M.

J Nucl Med. 2020 Feb;61(2):202-209. doi: 10.2967/jnumed.119.229542. Epub 2019 Jul 19.

PMID:
31324713
10.

Connectomics and molecular imaging in neurodegeneration.

Bischof GN, Ewers M, Franzmeier N, Grothe MJ, Hoenig M, Kocagoncu E, Neitzel J, Rowe JB, Strafella A, Drzezga A, van Eimeren T; MINC faculty.

Eur J Nucl Med Mol Imaging. 2019 Dec;46(13):2819-2830. doi: 10.1007/s00259-019-04394-5. Epub 2019 Jul 11.

PMID:
31292699
11.

Prognostic value of Alzheimer's biomarkers in mild cognitive impairment: the effect of age at onset.

Altomare D, Ferrari C, Caroli A, Galluzzi S, Prestia A, van der Flier WM, Ossenkoppele R, Van Berckel B, Barkhof F, Teunissen CE, Wall A, Carter SF, Schöll M, Choo ILH, Grimmer T, Redolfi A, Nordberg A, Scheltens P, Drzezga A, Frisoni GB; Alzheimer’s Disease Neuroimaging Initiative.

J Neurol. 2019 Oct;266(10):2535-2545. doi: 10.1007/s00415-019-09441-7. Epub 2019 Jul 2.

PMID:
31267207
12.

Medial Temporal Lobe Disconnection and Hyperexcitability Across Alzheimer's Disease Stages.

Pasquini L, Rahmani F, Maleki-Balajoo S, La Joie R, Zarei M, Sorg C, Drzezga A, Tahmasian M.

J Alzheimers Dis Rep. 2019 May 15;3(1):103-112. doi: 10.3233/ADR-190121. Review.

13.

Level of education mitigates the impact of tau pathology on neuronal function.

Hoenig MC, Bischof GN, Onur ÖA, Kukolja J, Jessen F, Fliessbach K, Neumaier B, Fink GR, Kalbe E, Drzezga A, van Eimeren T; Alzheimer’s Disease Neuroimaging Initiative.

Eur J Nucl Med Mol Imaging. 2019 Aug;46(9):1787-1795. doi: 10.1007/s00259-019-04342-3. Epub 2019 Jun 10.

PMID:
31183635
14.

4D-CT-based motion correction of PET images using 3D iterative deconvolution.

Thomas L, Schultz T, Prokic V, Guckenberger M, Tanadini-Lang S, Hohberg M, Wild M, Drzezga A, Bundschuh RA.

Oncotarget. 2019 Apr 26;10(31):2987-2995. doi: 10.18632/oncotarget.26862. eCollection 2019 Apr 26.

15.

Effects of subthalamic deep brain stimulation on striatal metabolic connectivity in a rat hemiparkinsonian model.

Apetz N, Kordys E, Simon M, Mang B, Aswendt M, Wiedermann D, Neumaier B, Drzezga A, Timmermann L, Endepols H.

Dis Model Mech. 2019 May 24;12(5). pii: dmm039065. doi: 10.1242/dmm.039065.

16.

Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System.

van Eimeren T, Antonini A, Berg D, Bohnen N, Ceravolo R, Drzezga A, Höglinger GU, Higuchi M, Lehericy S, Lewis S, Monchi O, Nestor P, Ondrus M, Pavese N, Peralta MC, Piccini P, Pineda-Pardo JÁ, Rektorová I, Rodríguez-Oroz M, Rominger A, Seppi K, Stoessl AJ, Tessitore A, Thobois S, Kaasinen V, Wenning G, Siebner HR, Strafella AP, Rowe JB.

Alzheimers Dement (Amst). 2019 Apr 2;11:301-309. doi: 10.1016/j.dadm.2019.01.011. eCollection 2019 Dec.

17.

Thyroid hemiagenesis is combined with a variety of thyroid disorders.

Schneider C, Dietlein M, Faust M, Drzezga A, Schmidt M.

Nuklearmedizin. 2019 Jun;58(3):265-271. doi: 10.1055/a-0830-4425. Epub 2019 Apr 11.

PMID:
30974469
18.

Head-to-Head Comparison among Semi-Quantification Tools of Brain FDG-PET to Aid the Diagnosis of Prodromal Alzheimer's Disease.

Brugnolo A, De Carli F, Pagani M, Morbelli S, Jonsson C, Chincarini A, Frisoni GB, Galluzzi S, Perneczky R, Drzezga A, van Berckel BNM, Ossenkoppele R, Didic M, Guedj E, Arnaldi D, Massa F, Grazzini M, Pardini M, Mecocci P, Dottorini ME, Bauckneht M, Sambuceti G, Nobili F.

J Alzheimers Dis. 2019;68(1):383-394. doi: 10.3233/JAD-181022.

PMID:
30776000
19.

[Dopamine Transporter SPECT with I-123 labelled FP-CIT (DaTSCANTM)].

Tatsch K, Buchert R, Bartenstein P, Barthel H, Boecker H, Brust P, Drzezga A, la Fougère C, Gründer G, Grünwald F, Krause BJ, Kuwert T, Langen KJ, Rominger A, Sabri O, Schreckenberger M, Meyer PT.

Nuklearmedizin. 2019 Feb;58(1):5-16. doi: 10.1055/a-0807-8137. Epub 2019 Feb 15. German.

PMID:
30769368
20.

Dopamine metabolism of the nucleus accumbens and fronto-striatal connectivity modulate impulse control.

Hammes J, Theis H, Giehl K, Hoenig MC, Greuel A, Tittgemeyer M, Timmermann L, Fink GR, Drzezga A, Eggers C, van Eimeren T.

Brain. 2019 Mar 1;142(3):733-743. doi: 10.1093/brain/awz007.

PMID:
30753324
21.

FDG-PET underscores the key role of the thalamus in frontotemporal lobar degeneration caused by C9ORF72 mutations.

Diehl-Schmid J, Licata A, Goldhardt O, Förstl H, Yakushew I, Otto M, Anderl-Straub S, Beer A, Ludolph AC, Landwehrmeyer GB, Levin J, Danek A, Fliessbach K, Spottke A, Fassbender K, Lyros E, Prudlo J, Krause BJ, Volk A, Edbauer D, Schroeter ML, Drzezga A, Kornhuber J, Lauer M; FTLDc Study Group, Grimmer T.

Transl Psychiatry. 2019 Jan 31;9(1):54. doi: 10.1038/s41398-019-0381-1.

22.

Effective connectivity in the default mode network is distinctively disrupted in Alzheimer's disease-A simultaneous resting-state FDG-PET/fMRI study.

Scherr M, Utz L, Tahmasian M, Pasquini L, Grothe MJ, Rauschecker JP, Grimmer T, Drzezga A, Sorg C, Riedl V.

Hum Brain Mapp. 2019 Jan 30. doi: 10.1002/hbm.24517. [Epub ahead of print]

PMID:
30697878
23.

Prevalence of abnormal Alzheimer's disease biomarkers in patients with subjective cognitive decline: cross-sectional comparison of three European memory clinic samples.

Wolfsgruber S, Molinuevo JL, Wagner M, Teunissen CE, Rami L, Coll-Padrós N, Bouwman FH, Slot RER, Wesselman LMP, Peters O, Luther K, Buerger K, Priller J, Laske C, Teipel S, Spottke A, Heneka MT, Düzel E, Drzezga A, Wiltfang J, Sikkes SAM, van der Flier WM, Jessen F; Euro-SCD working group.

Alzheimers Res Ther. 2019 Jan 17;11(1):8. doi: 10.1186/s13195-018-0463-y.

24.

Integrative analysis of blood metabolomics and PET brain neuroimaging data for Parkinson's disease.

Glaab E, Trezzi JP, Greuel A, Jäger C, Hodak Z, Drzezga A, Timmermann L, Tittgemeyer M, Diederich NJ, Eggers C.

Neurobiol Dis. 2019 Apr;124:555-562. doi: 10.1016/j.nbd.2019.01.003. Epub 2019 Jan 9.

25.

Uptake in non-affected bone tissue does not differ between [18F]-DCFPyL and [68Ga]-HBED-CC PSMA PET/CT.

Hammes J, Hohberg M, Täger P, Wild M, Zlatopolskiy B, Krapf P, Neumaier B, Schomäcker K, Kobe C, Schmidt M, Dietlein M, Drzezga A.

PLoS One. 2018 Dec 20;13(12):e0209613. doi: 10.1371/journal.pone.0209613. eCollection 2018.

26.

Impact of different approaches to calculation of treatment activities on achieved doses in radioiodine therapy of benign thyroid diseases.

Hammes J, van Heek L, Hohberg M, Reifegerst M, Stockter S, Dietlein M, Wild M, Drzezga A, Schmidt M, Kobe C.

EJNMMI Phys. 2018 Dec 12;5(1):32. doi: 10.1186/s40658-018-0231-x.

27.

Monitoring Treatment Response to Erlotinib in EGFR-mutated Non-small-cell Lung Cancer Brain Metastases Using Serial O-(2-[18F]fluoroethyl)-L-tyrosine PET.

Abdulla DSY, Scheffler M, Brandes V, Ruge M, Kunze S, Merkelbach-Bruse S, Nogova L, Michels S, Fischer R, Riedel R, Büttner R, Persigehl T, Grau S, Galldiks N, Drzezga A, Kobe C, Wolf J.

Clin Lung Cancer. 2019 Mar;20(2):e148-e151. doi: 10.1016/j.cllc.2018.10.011. Epub 2018 Nov 5. No abstract available.

28.

Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0.

Law I, Albert NL, Arbizu J, Boellaard R, Drzezga A, Galldiks N, la Fougère C, Langen KJ, Lopci E, Lowe V, McConathy J, Quick HH, Sattler B, Schuster DM, Tonn JC, Weller M.

Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):540-557. doi: 10.1007/s00259-018-4207-9. Epub 2018 Dec 5.

29.

Correction: 18F-FIBT may expand PET for β-amyloid imaging in neurodegenerative diseases.

Grimmer T, Shi K, Diehl-Schmid J, Natale B, Drzezga A, Förster S, Förstl H, Schwaiger M, Yakushev I, Wester HJ, Kurz A, Yousefi BH.

Mol Psychiatry. 2018 Nov 21. doi: 10.1038/s41380-018-0302-3. [Epub ahead of print]

PMID:
30464328
30.

Quantitative assessment of 18F-FDG PET in patients with Hodgkin lymphoma: is it significantly affected by contrast-enhanced computed tomography attenuation correction?

Voltin CA, Mettler J, Boellaard R, Kuhnert G, Dietlein M, Borchmann P, Drzezga A, Kobe C.

Nucl Med Commun. 2019 Mar;40(3):249-257. doi: 10.1097/MNM.0000000000000956.

PMID:
30461699
31.

Discovery of 18F-JK-PSMA-7, a PET Probe for the Detection of Small PSMA-Positive Lesions.

Zlatopolskiy BD, Endepols H, Krapf P, Guliyev M, Urusova EA, Richarz R, Hohberg M, Dietlein M, Drzezga A, Neumaier B.

J Nucl Med. 2019 Jun;60(6):817-823. doi: 10.2967/jnumed.118.218495. Epub 2018 Nov 2.

32.

The Network Degeneration Hypothesis: Spread of Neurodegenerative Patterns Along Neuronal Brain Networks.

Drzezga A.

J Nucl Med. 2018 Nov;59(11):1645-1648. doi: 10.2967/jnumed.117.206300. Review. No abstract available.

33.

AMYPAD Diagnostic and Patient Management Study: Rationale and design.

Frisoni GB, Barkhof F, Altomare D, Berkhof J, Boccardi M, Canzoneri E, Collij L, Drzezga A, Farrar G, Garibotto V, Gismondi R, Gispert JD, Jessen F, Kivipelto M, Lopes Alves I, Molinuevo JL, Nordberg A, Payoux P, Ritchie C, Savicheva I, Scheltens P, Schmidt ME, Schott JM, Stephens A, van Berckel B, Vellas B, Walker Z, Raffa N.

Alzheimers Dement. 2019 Mar;15(3):388-399. doi: 10.1016/j.jalz.2018.09.003. Epub 2018 Oct 16. Erratum in: Alzheimers Dement. 2019 Nov;15(11):1505.

34.

Thyroid Uptake and Effective Half-Life of Radioiodine in Thyroid Cancer Patients at Radioiodine Therapy and Follow-Up Whole-Body Scintigraphy Either in Hypothyroidism or Under rhTSH.

Bacher R, Hohberg M, Dietlein M, Wild M, Kobe C, Drzezga A, Schmidt M.

J Nucl Med. 2019 May;60(5):631-637. doi: 10.2967/jnumed.118.217638. Epub 2018 Oct 12.

PMID:
30315143
35.

The Role of Tau Imaging in Parkinsonian Disorders.

Hammes J, Drzezga A, van Eimeren T.

Curr Neurol Neurosci Rep. 2018 Oct 6;18(12):86. doi: 10.1007/s11910-018-0898-3. Review.

PMID:
30293094
36.

Daten zu Gunsten einer Levothyroxin-Substitution bei asymptomatischer latenter Hypothyreose.

Dietlein M, Drzezga A.

Nuklearmedizin. 2018 Sep;57(5):170-173. doi: 10.3413/Nukmed-0966-18-03. Epub 2018 Sep 28. German. No abstract available.

PMID:
30267398
37.

Outcome-based interpretation of early interim PET in advanced-stage Hodgkin lymphoma.

Kobe C, Goergen H, Baues C, Kuhnert G, Voltin CA, Zijlstra J, Hoekstra O, Mettler J, Drzezga A, Engert A, Borchmann P, Dietlein M.

Blood. 2018 Nov 22;132(21):2273-2279. doi: 10.1182/blood-2018-05-852129. Epub 2018 Aug 30.

PMID:
30166329
38.

Ablative Radioiodtherapie des Schilddrüsenkarzinoms.

Dietlein M, Drzezga A.

Nuklearmedizin. 2018 Aug;57(4):118-123. doi: 10.3413/Nukmed-0976-18-05. Epub 2018 Aug 20. German. No abstract available.

PMID:
30125924
39.

18F-FIBT may expand PET for β-amyloid imaging in neurodegenerative diseases.

Grimmer T, Shi K, Diehl-Schmid J, Natale B, Drzezga A, Förster S, Förstl H, Schwaiger M, Yakushev I, Wester HJ, Kurz A, Yousefi BH.

Mol Psychiatry. 2018 Aug 17. doi: 10.1038/s41380-018-0203-5. [Epub ahead of print] Erratum in: Mol Psychiatry. 2018 Nov 21;:.

PMID:
30120417
40.

Combined Early and Late [68Ga]PSMA-HBED-CC PET Scans Improve Lesion Detectability in Biochemical Recurrence of Prostate Cancer with Low PSA Levels.

Hohberg M, Kobe C, Täger P, Hammes J, Schmidt M, Dietlein F, Wild M, Heidenreich A, Drzezga A, Dietlein M.

Mol Imaging Biol. 2019 Jun;21(3):558-566. doi: 10.1007/s11307-018-1263-2.

PMID:
30105521
41.

Value of bone marrow biopsy in Hodgkin lymphoma patients staged by FDG PET: results from the German Hodgkin Study Group trials HD16, HD17, and HD18.

Voltin CA, Goergen H, Baues C, Fuchs M, Mettler J, Kreissl S, Oertl J, Klaeser B, Moccia A, Drzezga A, Engert A, Borchmann P, Dietlein M, Kobe C.

Ann Oncol. 2018 Sep 1;29(9):1926-1931. doi: 10.1093/annonc/mdy250.

42.

Mechanisms and modulators of cognitive training gain transfer in cognitively healthy aging: study protocol of the AgeGain study.

Wolf D, Tüscher O, Teipel S, Mierau A, Strüder H, Drzezga A, Baier B, Binder H, Fellgiebel A; German AgeGain study group.

Trials. 2018 Jun 27;19(1):337. doi: 10.1186/s13063-018-2688-2.

43.

An Efficient Approach to Perform MR-assisted PET Data Optimization in Simultaneous PET/MR Neuroimaging Studies.

Chen KT, Salcedo S, Gong K, Chonde DB, Izquierdo-Garcia D, Drzezga AE, Rosen B, Qi J, Dickerson BC, Catana C.

J Nucl Med. 2018 Jun 22. pii: jnumed.117.207142. doi: 10.2967/jnumed.117.207142. [Epub ahead of print]

44.

European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain 18 F-fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus.

Nobili F, Arbizu J, Bouwman F, Drzezga A, Agosta F, Nestor P, Walker Z, Boccardi M; EANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders.

Eur J Neurol. 2018 Oct;25(10):1201-1217. doi: 10.1111/ene.13728. Epub 2018 Jul 20.

PMID:
29932266
45.

Comparison of 18F-T807 and 18F-THK5117 PET in a Mouse Model of Tau Pathology.

Brendel M, Yousefi BH, Blume T, Herz M, Focke C, Deussing M, Peters F, Lindner S, von Ungern-Sternberg B, Drzezga A, Bartenstein P, Haass C, Okamura N, Herms J, Yakushev I, Rominger A.

Front Aging Neurosci. 2018 Jun 7;10:174. doi: 10.3389/fnagi.2018.00174. eCollection 2018.

46.

[The importance of molecular imaging (PET) in the diagnostics of dementia].

Tscheuschler M, Gebest M, Jessen F, Drzezga A.

Nervenarzt. 2018 Jul;89(7):843-856. doi: 10.1007/s00115-018-0533-1. German.

PMID:
29916030
47.

Metabolic Tumour Volume for Response Prediction in Advanced-Stage Hodgkin Lymphoma.

Mettler J, Müller H, Voltin CA, Baues C, Klaeser B, Moccia A, Borchmann P, Engert A, Kuhnert G, Drzezga AE, Dietlein M, Kobe C.

J Nucl Med. 2018 Jun 7. pii: jnumed.118.210047. doi: 10.2967/jnumed.118.210047. [Epub ahead of print]

48.

Clinical utility of FDG PET in Parkinson's disease and atypical parkinsonism associated with dementia.

Walker Z, Gandolfo F, Orini S, Garibotto V, Agosta F, Arbizu J, Bouwman F, Drzezga A, Nestor P, Boccardi M, Altomare D, Festari C, Nobili F; EANM-EAN Task Force for the recommendation of FDG PET for Dementing Neurodegenerative Disorders.

Eur J Nucl Med Mol Imaging. 2018 Jul;45(9):1534-1545. doi: 10.1007/s00259-018-4031-2. Epub 2018 May 19. Review.

49.

Diagnostic utility of 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) in asymptomatic subjects at increased risk for Alzheimer's disease.

Drzezga A, Altomare D, Festari C, Arbizu J, Orini S, Herholz K, Nestor P, Agosta F, Bouwman F, Nobili F, Walker Z, Frisoni GB, Boccardi M; EANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders.

Eur J Nucl Med Mol Imaging. 2018 Jul;45(9):1487-1496. doi: 10.1007/s00259-018-4032-1. Epub 2018 May 13. Review.

PMID:
29756163
50.

A Matter of Controversy: Is Radioiodine Therapy Favorable in Differentiated Thyroid Carcinoma?

Schmidt M, Görges R, Drzezga A, Dietlein M.

J Nucl Med. 2018 Aug;59(8):1195-1201. doi: 10.2967/jnumed.117.191338. Epub 2018 May 10. Review.

Supplemental Content

Loading ...
Support Center